PRINCETON, N.J., and PARIS, May 16, 2011 — STENTYS S.A. (STNT.PA), a medical technology company commercializing the world’s first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), is hosting a key symposium at this week’s EuroPCR congress. The symposium — “Does Size Matter? STENTYS® Self-Apposing™ Stent for STEMI and Complex Anatomy”—will be chaired by two internationally renowned cardiologists: Prof. Patrick W. Serruys, M.D., and Maurice Buchbinder, M.D. Registered participants of the EuroPCR congress are eligible to attend.
The STENTYS stent represents a major breakthrough when treating heart attacks: it is self-apposing, i.e. it “fits snugly” into the contour of a blood vessel, and its shape and diameter adapt to the anatomic changes of the coronary arteries during the post-AMI phase, avoiding a major complication of all other conventional stents: malapposition.
About STENTYS
Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic) and Gonzague Issenmann, STENTYS received CE-marking for its flagship products in 2010. Its self-apposing stent adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevents the malapposition problem associated with conventional stents. STENTYS has commenced marketing activities in several European countries.
This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.
